RxDoctor Payments Data

Ankitkumar Patel

Interventional Cardiology · Glen Ridge, NJNPI 1184820557

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Heartflow, Inc. at 35.8% of the total. 2025 is the largest year on record at $203,776, more than ten times the $1,620 reported in 2019. Among interventional cardiology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$407,874in general payments, 2019–2025

Across 857 payments — averaging $475.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$146K
  • Medtronic$103K
  • Abiomed$94K
  • Cathworks, Inc.$18K
  • Shockwave Medical, Inc$16K
  • Edwards Lifesciences$11K
  • plus $21K from 24 others
$310,465in research payments, 2019–2025

Across 36 payments — averaging $8624.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cathworks, Inc.$250K
  • Saranas, Inc.$41K
  • Abiomed$10K
  • Genetesis, Inc.$9K
  • ZOLL Circulation Inc$220

What the payments were for

  • Consulting fees$91,19322%
  • Speaking & faculty fees$186,59946%
  • Travel & lodging$91,74922%
  • Food & beverage$38,3169%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$407,874 in reported general payments places this provider in the 95th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$206,540
Medicare patients
1,751
Services billed
3,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban190$213,905
EntrestoSacubitril/Valsartan71$100,489
XareltoRivaroxaban35$46,758
MultaqDronedarone Hcl32$33,341
JardianceEmpagliflozin14$21,227
Metoprolol Succinate387$5,214
Atorvastatin Calcium358$4,180
Rosuvastatin Calcium155$3,895
Ranolazine ErRanolazine13$3,146
Valsartan51$1,597
ClopidogrelClopidogrel Bisulfate113$1,501
Amlodipine Besylate190$1,352
Losartan Potassium132$1,308
Diltiazem 24hr Er (Cd)Diltiazem Hcl31$1,061
Carvedilol64$1,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$212$100,48971 claims
Johnson & JohnsonXarelto$16$46,75835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 166 interventional cardiology providers in New Jersey.

Other interventional cardiology in Glen Ridge

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →